The new co-marketing and distribution partnership enables SureSeq™ NGS panel customers to purchase QIAGEN’s tertiary analysis software QIAGEN Clinical Insight (QCI®) Interpret as part of a complete SureSeq NGS workflow solution, unlocking comprehensive analysis from sample to report. QIAGEN Digital Insights bioinformatics bring over 25 years of expertise in expert-curated content, AI-powered proprietary algorithms and user-friendly tools to simplify NGS data analysis..

OGT, a leading global provider of genomic research and diagnostic solutions, proudly announces the opening of state-of-the-art facilities within the Oxford Technology Park. The move represents a multi-million-pound investment, fuelled by consistent company growth and growing customer demand. Equipped with cutting-edge technology, the facilities will drive development of OGT’s trusted SureSeq™ next generation sequencing (NGS) product portfolio, as well as deliver expert-led training and enhanced opportunities for collaboration...

OGT, a Sysmex Group Company and leading global provider of genomic research and diagnostic solutions, is delighted to announce its new partnership with Intelliseq, a genome informatics company and innovative provider of Next-Generation Sequencing (NGS) analysis solutions. This collaboration combines OGT's expansive SureSeq™ NGS portfolio with Intelliseq's state-of-the-art iFlow™ engine, resulting in a thorough and comprehensive NGS workflow—from sample to report...

A Sysmex Group Company, announces that IVDR-certification has been granted for eight CytoCell® fluorescence in situhybridisation (FISH) probes important for patient management in haematological cancers and prenatal conditions. This award places OGT as the first manufacturer of FISH probes to obtain the new IVDR certification on its products—demonstrating continued safety, reliability and effectiveness under this substantially more stringent regulation...

OGT™, A Sysmex Group Company, has revealed the expansion of support activities with CytoCell® University – an initiative that promises to partner with scientists to provide innovative and expert training on the basics of fluorescence in situ hybridisation (FISH). CytoCell University’s FISH training reaffirms OGT’s mission to support scientists around the globe and help customers advance genetic analysis.

Oxford Gene Technology (OGT), A Sysmex Group Company, has launched a transformative next-generation sequencing (NGS) panel for constitutional cytogenetics research. The CytoSure™ Constitutional NGS Panel contains the most up-to-date, hand-curated content for intellectual disability (ID) and developmental delay (DD) research. Delivering accurate and reliable detection of copy number variations (CNVs), single nucleotide variations....

Oxford Gene Technology (OGT), A Sysmex Group Company, is proud to announce that its new facility in Cambridge, UK, has achieved Medical Device Single Audit Program (MDSAP) certification of its quality management system (QMS). The announcement further solidifies the company’s aim to reach into molecular diagnostic markets following its first FDA clearance for eight Cytocell Aquarius® Haematology fluorescence in situ hybridisation (FISH) probes earlier this year....

State-of-the-art premises increases operational footprint and will host Sysmex global R&D facility. Oxford Gene Technology (OGT), A Sysmex Group Company, has celebrated the opening of its new facility in Cambridge, UK. The opening ceremony, which took place on 3rd June at the company’s new premises on the prestigious Cambridge Science Park, was attended by the Department for International Trade....

Oxford Gene Technology (OGT), The Molecular Genetics Company, has expanded its SureSeq™ portfolio with a complete library preparation solution for hybridisation-based target capture in NGS, making its market-leading coverage uniformity and expertise even more accessible. As well as updating and refining the library preparation workflow—including the addition of automation support—OGT’s SureSeq NGS Library Preparation Kit now includes a new....

Sysmex demonstrates confidence and investment in OGT and the United Kingdom. Oxford Gene Technology, The Molecular Genetics Company, has announced that it is expanding its Cytocell®operations with a move to a new facility in Cambridge, UK. Cytocell, OGT’s fluorescence in situ hybridisation (FISH) probe brand, will be moving into the significantly larger facility on the prestigious Cambridge Science Park, due to expansion...

Oxford Gene Technology (OGT), The Molecular Genetics Company, has announced that it has expanded its direct sales of Cytocell Fluorescence In Situ Hybridisation (FISH) products to include the Asia-Pacific (APAC) region. OGT will provide customers in Singapore, Malaysia, Vietnam, Australia, and New Zealand with enhanced local sales and support services via established affiliates of Sysmex Corporation, as well as via continued collaboration with existing distributors...

Powerful, flexible and easy-to-use analysis solution gets the most out of NGS data. Oxford Gene Technology (OGT), The Molecular Genetics Company, has announced the launch of the eagerly-anticipated update to its SureSeq™ Interpret software, included with purchases of SureSeq NGS panels. Designed to help researchers effortlessly translate cumbersome NGS data into meaningful results, OGT has leveraged its renowned bioinformatics expertise to...

Customers to benefit from Sysmex’s extensive operational footprint. Oxford Gene Technology (OGT), The Molecular Genetics Company, has announced that it is now directly selling Cytocell Fluorescence In Situ Hybridisation (FISH) products through several established affiliates of Sysmex Corporation in Europe following its acquisition last year....

Increased content provides even more flexibility for customisation. The Molecular Genetics Company, has expanded its SureSeq myPanel™ NGS Custom Cancer Panel content - now covering 120 fully optimised cancer related genes. The expanded content gives researchers even more freedom to customise their sequencing experiments, enabling focus on regions of interest, saving time...

New website makes it easier to access expert FISH advice. Oxford Gene Technology (OGT), The Molecular Genetics Company, has launched a new version of itsCytocell® fluorescence in situ hybridisation (FISH) probes website - designed to provide a wealth of information and advice, offer refined functionality, and be easy-to-use. Cytocell is well known for its complete and comprehensive range of FISH...

Oxford Gene Technology (OGT), The Molecular Genetics Company, today announced that it has signed an agreement to be acquired by Sysmex Corporation (Sysmex), a Japanese in vitro diagnostic company.

Sysmex will acquire all of OGT’s shares, gaining access to OGT’s genetic analysis technologies and expertise in the cytogenetics domain. OGT will become a wholly owned subsidiary of Sysmex. Further terms of the agreement are not being disclosed....

New SureSeq myPanel™ NGS Custom Cancer Panel content covers a wider range of cancer types with excellent coverage uniformity for confident results

Oxford Gene Technology (OGT), The Molecular Genetics Company, has expanded its SureSeq myPanel™ NGS Custom Cancer Panel content. The expansion comes in response to NGS becoming ever more important for research into an increasing number of cancer types...

Addition of three new sarcoma probes produces largest portfolio on the market

Oxford Gene Technology (OGT), The Molecular Genetics Company, has expanded its range of Cytocell Aquarius^® fluorescence in situ hybridisation (FISH) probes for pathology. OGT has introduced three new probes: FUS Breakapart and FOXO1 Breakapart, both carrying the CE-IVD label – and TFE3 Breakapart, for research use only. This expansion reinforces OGT’s commitment to providing the most comprehensive and up-to-date range available...

SureSeq myPanel™ NGS Custom FH Panels enable streamlined investigation of FH and customisation of content

Oxford Gene Technology (OGT), The Molecular Genetics Company, has expanded its customisable SureSeq™ NGS panel range with the launch of the SureSeq myPanel™ NGS Custom FH Panel – allowing fast and cost-effective study of variants in familial hypercholesterolemia (FH). The new panel delivers both single nucleotide variation (SNV) and copy number variation (CNV) detection on a single small NGS panel assay...

New probes facilitate diagnosis and stratified treatment of NSCLC

Oxford Gene Technology (OGT), The Molecular Genetics Company, has launched two new CE-IVD labelled fluorescence in situ hybridisation (FISH) probes, further expanding its extensive lung cancer portfolio. The Cytocell Aquarius^® ROS1 Plus Breakapart and RET Breakapart probes* specifically and accurately detect rearrangements in the genome associated with the most common form of lung cancer — non-small cell lung cancer (NSCLC)...

OGT workshop at ESHG highlighted the impact of exon-level CNV analysis on accurate detection of genetic disorders

Oxford Gene Technology (OGT), The Molecular Genetics Company, held an exclusive workshop exploring the power of exon-focused microarrays in enhancing genetic syndrome research at the recent European Human Genetics Conference (ESHG). Three expert clinical researchers from across the globe shared their knowledge of enhanced CNV detection with OGT’s CytoSure™ Constitutional v3 array, helping viewers...

Cytocell Aquarius^® probe range expanded in response to high customer demand

Oxford Gene Technology (OGT), The Molecular Genetics Company, has further expanded its extensive catalogue of fluorescence in situ hybridisation (FISH) products with nine new Cytocell Aquarius^® probes. The range now includes ETV6 Proximal Probe Green, ETV6 Distal Probe Red, MPO Probe Red, TP53 Probe Green, NUP214 Probe Red, DEK Probe Green, TAS2R1 (5p15.31) Probe Green, Chromosome 9 Satellite III Probe...

New SureSeq™ FFPE DNA Repair Mix delivers excellent sequencing data for confident variant calling from minimal DNA input

Oxford Gene Technology (OGT), The Molecular Genetics Company, has introduced its SureSeq™ FFPE DNA Repair Mix — optimised to repair a broad range of damage in formalin-fixed, paraffin-embedded (FFPE) derived DNA. The mix effectively repairs DNA damage, improving library yields, on-target rates and mean target coverage, while removing fixation and storage artefacts and reducing the amount of starting...

Cost-effective, ready-to-use kit enables reliable co-deletion investigations

Oxford Gene Technology (OGT), The Molecular Genetics Company, has launched its CE-IVD labelled Cytocell Aquarius^® 1p36/1q25 and 19q13/19p13 Deletion Probe Kit*, a cost-effective fluorescence in situ hybridisation (FISH) kit for the reliable investigation of glial tumours. Co-deletion of the 1p36.32 and 19q13.33 regions are frequently reported in many classes of gliomas.^1,2 Moreover, the presence of a...

Cytocell Chromoprobe Multiprobe^® non-human FISH probes set to benefit animal husbandry and research

Oxford Gene Technology (OGT), The Molecular Genetics Company, has developed a new range of non-human fluorescence in situ hybridisation (FISH) probes, for pig, chicken and mouse. The probes were developed as part of an Innovate UK knowledge transfer partnership (KTP) funded project in collaboration with the University of Kent, and was given an ‘outstanding’ award reserved for the top 10% of KTP projects...

Clinical researchers can now detect copy-neutral factors alongside powerful CNV detection with the addition of SNP probes to the popular CytoSure™ Constitutional v3 array content

Oxford Gene Technology (OGT), The Molecular Genetics Company, has announced the launch of its new CytoSure Constitutional v3 +LOH array for comprehensive genetic analysis of developmental delay disorders. Alongside the latest content for exon-level copy number variation (CNV) coverage, research-validated single nucleotide polymorphism (SNP) probes facilitate detection of loss of heterozygosity (LOH), enabling insightful and...

Proprietary technology allows superior LOH detection in challenging samples

Oxford Gene Technology (OGT), The Molecular Genetics Company, has entered into a deal with Baylor Miraca Genetics Laboratories (BMGL), licensing the use of OGT’s proprietary single nucleotide polymorphism (SNP) array probe technology. This novel technology overcomes the limitations of restriction enzyme-based SNP probe approaches previously employed at BMGL for loss of heterozygosity (LOH) detection, allowing accurate array-based analysis of low...

Cost-effective, ready-to-use kit enables appropriate testing strategies for reliable diagnoses

Oxford Gene Technology (OGT), The Molecular Genetics Company, has launched its CE-IVD labelled Cytocell Aquarius^®P16/3c/7c/17c Probe Kit, a cost-effective, ready-to-use fluorescence in situ hybridisation (FISH) probe kit for non-invasive detection of bladder cancer — for sale in Europe. Bladder cancer is becoming increasingly prevalent, and in 2012 was reported as the 5^th most common cancer in Europe¹. While...

New whitepaper demonstrates how customisable, medically focused array designs complement NGS for clinical genetics research   

Oxford Gene Technology (OGT), The Molecular Genetics Company, has been speaking to genetic scientists, Dr Tracey Lewis (Associated Regional and University Pathologists [ARUP] Laboratories) and Dr Emily Farrow (Children’s Mercy Hospital), in a new whitepaper entitled “Examining the Medical Exome”. This whitepaper describes their experiences with OGT’s CytoSure™ Medical Research Exome Array and explores how this customisable array targets a variety of genetic disorders to...

Cost-effective pathology probes offer consistent and accurate results for a growing number of targets

Oxford Gene Technology (OGT), The Molecular Genetics Company, is extending its portfolio of Cytocell^® Pathology FISH probes with the addition of eight new probes. OGT offers the widest range of fluorescence in situ hybridisation (FISH) probes on the market, delivering a cost-effective and reliable solution for anyone engaged in FISH. The new additions to the Cytocell range include high-quality pathology FISH probes for 1q25, 1p36, 19p13, 19q13...

Learn about the next generation of microarrays in one of the best attended workshops of the conference

Oxford Gene Technology (OGT), The Molecular Genetics Company, has made its European Human Genetics (ESHG) Conference workshop freely available to view online. The presentation, entitled “The Next Generation of Microarrays: Identifying a Broader Range of Genetic Syndromes Using Exon–Focussed Array Designs”, took place at the ESHG conference in Glasgow, UK on 8th June 2015. OGT also launched its CytoSure™ Constitutional v3 Arrays at...

High-resolution exon-focused arrays with enhanced content from the Deciphering Developmental Disorders study

Oxford Gene Technology (OGT), The Molecular Genetics Company, is today launching a new range of arrays at the European Society of Human Genetics (ESHG) Conference in Glasgow, UK, that are dedicated to elucidating the underlying causes of developmental delay. OGT’s unique Cytosure™ Constitutional v3 arrays have been developed following its recent licence agreement with the Wellcome Trust Sanger Institute to access the...

The time needed to genetically sequence the bacteria causing tuberculosis (Mtb) from patient samples has been reduced from weeks to days using a new technique developed by a UCL-led team.

This could help health service providers to better treat disease, control transmission of this infection, and monitor outbreaks. Tuberculosis (TB) disease rates in some parts of London are as high as in Sub-Saharan Africa, and drug-resistant strains are becoming increasingly common. These require specific treatments, and if doctors know that a bug is resistant they can start therapy earlier, often leading to better outcomes. Whole genome sequencing reveals the complete...

Oxford Gene Technology (OGT), The Molecular Genetics Company, has teamed up with clinical research experts in a new article available online, discussing the role of next generation sequencing (NGS) in cancer medicine.

The article, entitled “The role of NGS in stratified cancer medicine”, presents a valuable resource to better understand the present and the future of NGS in stratified cancer medicine, detailing the most relevant aspects of this revolutionary technology. A key focus of current cancer research is developing the use of stratified medicine. The approach is highly advantageous in guiding effective therapy as it profiles the genetic makeup of individual tumour samples...

New case study follows the successful adoption of OGT’s CytoSure™ platform at Sheffield Children's NHS Foundation Trust  

Oxford Gene Technology (OGT), The Molecular Genetics Company, explores how Sheffield Children's NHS Foundation Trust has seamlessly transferred to its CytoSure™ ISCA 8x60k platform, in a new case study entitled Evaluating and switching to CytoSure microarrays. As the result of a highly stringent National Health Service (NHS) tender for the supply of oligo-based cytogenetics research arrays, CytoSure was selected based on...

Oxford Gene Technology (OGT), The Molecular Genetics Company, has launched its CytoSure™ Medical Research Exome Array at the 64th Annual Meeting of the American Society of Human Genetics (ASHG)

Developed with leading molecular genetics experts at Emory University, the new array is highly targeted and exon-focussed, enabling the accurate detection of medical research relevant microdeletions and microduplications. The high-density array (1x1M) contains over 4,600 hand-curated genes, which have been grouped into disease- and syndrome-specific panels. This research-validated gene content can also be customised for...

Oxford Gene Technology (OGT), The Molecular Genetics Company, has announced the launch of a new high-resolution, high-throughput pre-implantation genetic screening (PGS) microarray aimed at improving embryo screening for in vitro fertilisation (IVF).

The CytoSure™ Embryo Screen Array offers eight arrays of 60,000 spots for high-resolution genome-wide aneuploidy and copy number detection in pre-implantation embryos. The microarray can screen up to 14 embryos on a single slide, which is particularly useful in embryo banking — a common procedure for advanced maternal age samples — enabling the confident identification of the best embryo for implantation.

Oxford Gene Technology (OGT), The Molecular Genetics Company, has announced that following its acquisition of Cytocell in March, it will directly sell Cytocell products to the North American market.

New and existing Cytocell customers in North America will now benefit from OGT’s expert and experienced sales and support infrastructure, which will be further enhanced through additional appointments in the coming months. OGT’s acquisition of Cytocell saw the addition of a portfolio of Fluorescence In Situ Hybridisation (FISH) probes to its CytoSure™ cytogenetics array and Genefficiency™ next generation sequencing products and...

Oxford Gene Technology (OGT), The Molecular Genetics Company, has released a new application note detailing the technical evaluation of two DNA labelling kits, where OGT’s CytoSure Genomic DNA Labelling Kits were found to be quicker and more accurate than a leading alternative.

Achieving efficient and uniform labelling of both test and reference DNA samples is critical for aCGH studies, enhancing data accuracy and interpretation. By ensuring greater accuracy, OGT’s kits vastly improve the identification of breakpoints and even the smallest aberrations, providing robust and invaluable insights into the underlying cause of genetic disorders... 

Oxford Gene Technology (OGT), The Molecular Genetics Company, has produced a new whitepaper titled ‘Comprehensive genomic analysis – complementing sequencing with high-resolution CNV detection’.

The free, downloadable whitepaper provides researchers with an opportunity to explore the latest strategies in the genomic characterisation of complex disorders, and to discover how, when used alongside sequencing, microarrays play a vital role in delivering accurate detection of point mutations and single exon copy number aberrations. The new whitepaper explains how utilising a range of available tools builds a more complete picture of inherently complex genetic disorders...

OGT releases new CytoSure™ Interpret Software to enhance CNV detection

Oxford Gene Technology (OGT), The Molecular Genetics Company, is pleased to announce the latest version (4.5.3) of its class-leading CytoSure™ Interpret Software. Complimentary with all CytoSure array purchases, CytoSure Interpret Software is a powerful and easy-to-use package for the analysis of aCGH data, the gold-standard for copy number variation (CNV) detection. Offering an impressive combination of advanced features, including Automatic Aberration Classification, the software allows the choice of standardised or customised user-defined data analysis....

Emory’s Professor Madhuri Hegde to discuss OGT’s new molecular arrays at ACMG 2014

Oxford Gene Technology (OGT), The Molecular Genetics Company, has expanded its range of research-validated CytoSure Molecular Arrays to investigate DNA copy number variation (CNV) underlying a variety of genetic disorders. Designed and optimised in collaboration with experts at Emory Genetics Laboratory (EGL; Atlanta, USA), the arrays are the ideal complement to DNA sequencing, providing a particularly powerful tool for investigating the variety of aberrations underlying genetic disorders. Professor Madhuri Hegde, Professor of Human Genetics at Emory University School of Medicine, will discuss the design and application of these arrays at the American College of Medical Genetics (ACMG) meeting on Thursday 27 March 2014...

Quality-driven tender selects OGT after extensive validation 

Oxford Gene Technology (OGT), provider of innovative genetics research and biomarker solutions to advance molecular medicine, has been awarded a significant tender by the UK National Health Service for the supply of oligo-based arrays for cytogenetics. Involving the cooperation of a number of health authorities, the tender’s comprehensive validation process sets an excellent example for future procurement procedures...

OGT provides insight on NGS enrichment optimisation

Oxford Gene Technology (OGT), provider of innovative genetics research and biomarker solutions to advance molecular medicine, has produced a free whitepaper titled ‘The importance of enrichment assay choice and optimisation for confident variant detection.’ The paper investigates the main strategies employed to optimise target enrichment for next generation sequencing (NGS) assays, assisting researchers to make informed decisions when designing studies...

OGT’s ASHG 2013 workshop highlights the need for comprehensive genomic analysis

Oxford Gene Technology (OGT), provider of innovative genetics research and biomarker solutions to advance molecular medicine, has made a recording of its recent American Society of Human Genetics (ASHG) workshop available to watch online. The oversubscribed workshop, titled “Complementing next generation sequencing experiments with high-resolution copy number variation detection”, was recorded at the meeting in Boston (US) on the 25^th of October 2013...

OGT publishes survey results

Oxford Gene Technology (OGT), provider of innovative genetics research and biomarker solutions to advance molecular medicine, has released the results from a recent survey of researchers using next generation sequencing. The survey was designed to investigate current trends in NGS usage and determine future demands; to aid OGT in continuing to deliver high-quality, up-to-date services and provide insightful, relevant customer resources...

Rapidly identify meaningful results with OGT’s Genefficiency™ NGS Report

Oxford Gene Technology (OGT), provider of innovative genetics research and biomarker solutions to advance molecular medicine, is offering the research community a snapshot of its user-friendly Genefficiency™ NGS Variant Analysis Report software, with the release of a free-to-download demo version. The interactive report efficiently manages the complete data analysis process for NGS workflows and delivers fully annotated data, allowing the identification of meaningful results in just a few simple mouse clicks...

OGT provides insight into choice of NGS methods

Oxford Gene Technology (OGT), provider of innovative genetics research and biomarker solutions to advance molecular medicine, has produced a new, free-to-download whitepaper titled ‘When to use targeted resequencing — Choosing the right NGS method.’ The paper aims to assist researchers when planning NGS strategies by providing a detailed review of the major resequencing methods. Comparing and contrasting method suitability, the paper also examines the significant impact of data analysis, as well as time and cost considerations...

Introductory 3 for 2 exome sequencing and analyses offer

Oxford Gene Technology (OGT), provider of innovative genetics research and biomarker solutions to advance molecular medicine, has extended its high-quality whole exome sequencing services with a targeted Familial Sequencing and Analysis Service. Ideal for investigators of inherited disease, the new service delivers multi-genome analysis of related samples for the detection of causative, de novo and disease susceptibility mutations. With a fully optimised workflow, OGT offers the entire targeted next generation sequencing pipeline, from project design through to end-point mutation discovery and extensive variant annotation...

Simultaneous detection of CNVs, SNPs and LOH on a single array using any reference sample

Oxford Gene Technology (OGT), provider of innovative genetics research and biomarker solutions to advance molecular medicine, has released a new microarray to improve the accuracy and efficiency of cancer research. The CytoSure™ Cancer +SNP array (4x180k) combines long oligo array comparative genomic hybridisation (aCGH) probes with fully validated single nucleotide polymorphism (SNP) content, providing the superior detection of both copy number variations (CNVs) and loss of heterozygosity (LOH) on a single chip. The array has been optimised in collaboration with Professor Jacqueline Schoumans from the Lausanne University Hospital in Switzerland, an expert in both aCGH and cancer genomics...

Oxford Gene Technology (OGT), provider of innovative genetics research and biomarker solutions to advance molecular medicine, has produced a new, free-to-download application note on combined array comparative genomic hybridisation (aCGH) and single nucleotide polymorphism (SNP) arrays.

The application note, titled ‘Detecting copy number variants and runs of homozygosity on a single array — challenges and applications’ aims to support researchers in navigating this combined approach for the simultaneous detection of copy number variations (CNVs) and runs of homozygosity (ROH). aCGH has established itself as the “gold-standard” platform for array-based CNV detection. Recent advances have enabled the combination of aCGH probes for CNV detection with probes able to detect SNPs...

Placement student, David Blaney achieves UK Life Sciences Placement of the Year award

Oxford Gene Technology (OGT), provider of innovative genetics research and biomarker solutions to advance molecular medicine, is proud to announce the achievements of placement student David Blaney. Following a nomination by the company, David earned this year’s BBSRC-sponsored Placement of the Year award. The award was part of the inaugural Cogent UK Life Science Skills Awards event, which took place on the 16^th May and saw winners take to the stage to receive awards across ten categories...

Optimising next generation DNA and RNA sequencing studies

Build and dress a snowman with OGT’s interactive Share-a-Snowman Game

Streamlined strategy and analysis that delivers meaningful results